Asoprisnil (J867): A selective progesterone receptor modulator for gynecological therapy

Steroids

Volumn 68, Issue 10-13, 2003, Pages 1019-1032

  DeManno, Deborah ^a   Elger, Walter ^b   Garg, Ramesh ^a   Lee, Ronald ^a   Schneider, Birgitt ^b   Hess Stumpp, Holger ^c   Schubert, Gerd ^c   Chwalisz, Kristof ^a  

^a TAP PHARMACEUTICAL PRODUCTS INC   (United States)

^b EnTec GmbH   (Germany)

^c BAYER PHARMA AG   (Germany)

Author keywords

Asoprisnil; Endometriosis; Gynecological therapy; Selective progesterone receptor modulator; Uterine fibroids

Indexed keywords

ANTIGESTAGEN; ASOPRISNIL; DRUG METABOLITE; ESTRADIOL BENZOATE; ESTROGEN; ESTROGEN RECEPTOR; GESTAGEN; J 1912; J 912; LEVONORGESTREL; MIFEPRISTONE; MINERALOCORTICOID RECEPTOR; ONAPRISTONE; PROGESTERONE; PROGESTERONE RECEPTOR MODULATOR; PROMEGESTONE; UNCLASSIFIED DRUG;

AMENORRHEA; AREA UNDER THE CURVE; BINDING AFFINITY; BREAKTHROUGH BLEEDING; CHRONIC TOXICITY; CONFERENCE PAPER; DOSE RESPONSE; DRUG METABOLISM; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG SELECTIVITY; DRUG TOLERABILITY; ENDOMETRIOSIS; ENDOMETRIUM; ENDOMETRIUM ATROPHY; GUINEA PIG; HUMAN; LABOR INDUCTION; LUTEOLYSIS; MENSTRUAL CYCLE; MONKEY; NONHUMAN; OVARIECTOMY; PREGNANCY; PREMATURE LABOR; UTERUS MYOMA; UTERUS WEIGHT; VAGINA;

ANIMALIA; CAVIA; CAVIA PORCELLUS; MACACA FASCICULARIS; ORYCTOLAGUS CUNICULUS; SUS SCROFA;

EID: 0347627638     PISSN: 0039128X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.steroids.2003.09.008     Document Type: Conference Paper

References (14)

1. Elger W., Bartley J., Schneider B., Kaufmann G., Schubert G., Chwalisz K. Endocrine pharmacological characterization of progesterone antagonists and progesterone receptor modulators with respect to PR-agonistic and antagonistic activity. Steroids. 65(10/11):2000;713-723.
2. Chwalisz K., Brenner R.M., Fuhrmann U.U., Hess-Stumpp H., Elger W. Antiproliferative effects of progesterone antagonists and progesterone receptor modulators on the endometrium. Steroids. 65(10/11):2000;741-751.
3. Chwalisz K, Elger W, McCrary K, Beckman P, Larsen L. Reversible suppression of menstruation in normal women irrespective of the effect on ovulation with the novel selective progesterone receptor modulator (SPRM) J867. J Soc Gynecol Invest 2002;9(Suppl 1) [abstract 49].
4. Rowan B.G., O'Malley B.W. Progesterone receptor coactivators. Steroids. 65:2000;545-549.
5. Shimuzu Y., Yarborough C., Elger W., Chwalisz K., Osawa Y. Inhibition of aromatase activity in human placental microsomes by 13-retro-antiprogestins. Steroids. 60:1994;234-238.
6. Milgrom E., Atger M., Perrot M., Baulieu E.E. Progesterone in the uterus and plasma. VI. Uterine progesterone receptors during the estrus cycle and implantation in the guinea pig. Endocrinology. 90:1972;1071-1078.
7. Gemzell-Danielsson K., Hamberg M. The effect of antiprogestin (RU 486) and prostaglandin biosynthesis inhibitor (naproxen) on uterine fluid prostaglandin F2 alpha concentrations. Hum. Reprod. 9:1994;1626-1630.
8. D'Erchia A.M., Gissi C., Pesole G., Saccone C., Arnason U. The guinea-pig is not a rodent. Nature. 381(6583):1996;597-600.
9. Chwalisz K. The use of progesterone antagonists for cervical ripening and as an adjunct to labour and delivery. Hum. Reprod. 9(Suppl. 1):1994;131-162.
10. Psychoyos A. Uterine receptivity for nidation. Ann. N.Y. Acad. Sci. 476:1986;36-42.
11. Psychoyos A. Hormonal control of ovoimplantation. Vitam. Horm. 31:1973;201-256.
12. Bacic M., de Casparis W., Diczfalusy E. Failure of large doses of ethinyl estradiol to interfere with early embryonic development in the human species. Am. J. Obstet. Gynecol. 4:1970;531-534.
13. Chwalisz K., Garg R., Brenner R.M., Schubert G., Elger W. Selective progesterone receptor modulators (SPRMs). A novel therapeutic concept in endometriosis. Ann. N.Y. Acad. Sci. 955:2002;373-387.
14. Chwalisz K, Lamar Parker R, Williamson S, Larsen L, McCrary K, Elger W. Treatment of uterine leiomyomas with the novel selective progesterone receptor modulator (SPRM) J867. J Soc Gynecol Invest 2003;10(2) [abstract 636].